Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2007-01-23
2007-01-23
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S455000, C424S457000, C424S489000, C424S490000, C424S491000
Reexamination Certificate
active
08451120
ABSTRACT:
Methods and reagents for improved treatment and diagnostic imaging, particularly of cancer. The methods and reagents utilize specific targeting of treatment and imaging ligands to the targeted tumor, or specific organ or tissue, in association with extracorporeal affinity adsorption of the targeting ligand. The targeted species include antibodies as well as other peptides with specific affinity to the targeted tumor organ or tissue. Included are hybrid targeting molecules, such as hybrid F(ab′)2, with one binding site specific for the target and the other binding site specific for the targeted treatment or visualization ligand. The affinity adsorption devices may include adsorbents specific to one or more of the components of the targeting molecule-targeted ligand moiety. The methods provide for improved treatment, particularly in cancer and HIV, by increasing the concentration in the tumor and decreasing the concentration in the rest of the body, thus reducing its toxicity and enabling the use of high doses of drugs and other treatment agents. Improved visualization of cancer is provided by increased concentration of visualization ligand in the cancer and reduced concentration in the blood and normal tissues.
REFERENCES:
patent: 4620977 (1986-11-01), Strahilevitz
patent: 5374548 (1994-12-01), Caras
patent: 5431897 (1995-07-01), Welt et al.
patent: 5474772 (1995-12-01), Maddock
patent: 5527528 (1996-06-01), Allen et al.
patent: 5620689 (1997-04-01), Allen et al.
patent: 0302673 (1989-02-01), None
patent: 0349127 (1990-01-01), None
patent: 9317715 (1993-09-01), None
patent: 9408043 (1995-02-01), None
patent: 9515770 (1995-06-01), None
Gregoriadis & Florence (Drugs, 1993, 45:15-28.
Gabizon (J. of Liposome Res, 1995, 5:704-710).
Hird et al (in “Genes & Cancer”)Carney et al Ed, John Wiley & Sons, 1990, pp. 83-89.
Harris et al (Tibtech, 11:42-44, 1993).
Fahey et al (Clin Exp. Immunol., 1992, 88:1-5).
Martin et al (Biochemistry, 20:4229-4238), 1981.
Fanger et al (FASEB, 4;2846-2849), 1990.
Wong et al (Immunology, 81:280-284), 1994.
Collins et al (Cancer Res., 47:735-739), 1987.
C. Lollo et al., Nuclear Medicine Communications, vol. 15, 1994, pp. 483-491.
James L. Lear et al., Radiology, vol. 179, 1991, pp. 509-512.
G. W. Welling et al., Journal of Chromatography, vol. 512, 1990, pp. 337-343.
G. S. David, Biochem. Biophys. Res. Commun., vol. 48, 1972, pp. 464-471.
A. R. Fitzberg et al., Proc. Nat. Acad. Sci. U.S.A., vol. 85, 1988, pp. 4025-4029.
M. belles-Isles and M. Page, British Journal of Cancer, vol. 41, 1980, pp. 841 42.
R. Yang et al., Antibody Immunoconjugates Radiopharmaceuticals, vol. 5(2), 1992, pp. 201-207.
P. Gold and S. O. Freedman, J. Exp. Med., vol. 121, 1965, pp. 439-443.
S. Sell and F. F. Becker, J. Nat. Cancer Inst., vol. 60, 1978, pp. 19-26.
M. Belles-Isles and M.Page, Int. J. Immunopharmacol., vol. 3, 1981, pp. 97-102.
M. Belles-Isles and M. Page, Brit. J. Cancer, vol. 141, 1980, pp. 841-842.
H. Lee et al., Cancer Immunol. Immunotherapy, vol. 5, 1978, pp. 201-206.
David L. Dunn, Arch. Surg., vol. 128, 1993, pp. 1274-1280.
H. Zhao et al., Bioconjug. Chem., vol. 3, 1992, pp. 549-553.
V. S. Reddy and C. H. Ford, Anticancer Research, vol. 13(6A), 1993, pp. 2077-2078.
I. Ahmad and T. M. Allen, Cancer Research, vol. 52, 1992, pp. 4817-4820.
King et al., Antibody Immunoconjugates and Radiopharmaceuticals, vol. 5(2), 1992, pp. 159-170.
M. McClure in: “Encyclopedia of Immunology”, Ivan M. Roitt Ed., Academic Press, 1992, pp. 695-700.
K. Y. Hostetler et al., Antimicrob Agents Chemotherapy, vol 38(12), 1994, pp. 2792-2797.
D. D. Lasic and D. Papahadjopoulos, Science, vol. 267, pp. 1275-1276, Mar. 3, 1995.
K. Norrgren et al., Antibody Immunoconjugates and Radiopharmaceuticals, vol. 4 (4), pp. 907-914, 1991.
C. Nicolau and A. Cudd, Critical Reviews in Therapeutic Drug Carrier Systems, vol. 6 (3), 1989.
J. Barbet et al, Journal of Supramolecular Structure and Cellular Biochemistry, vol. 16, pp. 243-258, 1981.
P. Machy and L. D. Leserman, Biochimica Biophysica Acta, vol. 730, pp. 313-320, 1983.
G. Adrian and L. Huang, Biochemistry, vol. 18 (25), pp. 5610-5614, 1979.
L. D. Leserman et al., Nature, vol. 293, pp. 226-228, Sep. 17, 1981.
I. Ahmad et al., Cancer Research, vol. 53, pp. 1484-1488, Apr. 1, 1993.
Qian He-nian and Li Wen-jin, Chinese Medical Journal, vol. 106 (5), pp. 343-347, 1993.
P. Machy et al., Proc. Natl. Acad. Sci. USA, vol. 85, pp. 8027-8031, Nov. 1988.
K. Maruyama et al., Proc. Natl. Acad. Sci. USA, vol. 87, pp. 5744-5748, Aug. 1990.
K. K. Matthay et al., Cancer Research, vol. 44, pp. 1880-1886, May 1984.
Y. Hashimoto et al., Cancer Research, vol. 43, 5328-5334, Nov. 1983.
P. Machy et al., The Journal of Immunology, vol. 136 (8), pp. 3110-3115, Apr. 15, 1986.
R. B. Bankert et al., Cancer Research, vol. 49, pp. 301-308, Jan. 15, 1989.
S. S. Williams et al., Cancer Research, vol. 53, pp. 3964-3967, Sep. 1, 1993.
K. Maruyama et al., Proc. Natl. Acad. Sci. USA, vol. 87, pp. 5744-5748, Aug. 1990.
D. D. Lasic et al., Biochimica et Biophysica Acta, vol. 1070, pp. 187-192, 1991.
D. Papahdjopoulus et al., Proc. Natl. Acad. Sci. USA, vol. 88, pp. 11460-11464, Dec. 1991.
“Liposomes as Drug Carriers, Recent Trends and Progress.” Gregory Gregoriadis, Editor, John Wiley and Sons Pub., New York, 1988.
P. N. Shek and R. F. Barber in ref. 41, pp. 145-155.
G. Hedlund et al. in ref 41, pp. 167-182.
Irma A. J. M. Bakker-Woudenberg et al., in ref. 41, pp. 325-336.
A. A. Gabizon and Y. Barenholz, in ref. 41, pp. 365-379.
S. E. Seltzer, in Ref. 41, pp. 509,525.
R.J.Y. Ho and L. Huang, in ref. 41, pp. 527-547.
N. Weiner and Chia-ming Chiang, in ref. 41, pp. 599-607.
T. Ghose et al., in ref. 41, pp. 697-707.
T. D. Heath, in ref. 41, pp. 709-717.
L. Leserman, in ref. 41, pp. 719-726.
D. Collins, in ref. 41, pp. 761-770.
C. Hixs and T. R. Witty, Clinical Chemistry, vol. 31 (6), abstract #136 p. 929, 1985.
J. P. O'Connell et al., Clin. Chem. 31/9, pp. 1424-1426, 1985.
Weckenmann, et al.—Arzneim-Forsch/Drug Res. 39 (I), Nr. 3 (1989) pp. 415-420.
B. Geiger, et al.—Eur. J. Immunol. 1981. 11: pp. 710-716.
Ahmad et al, Cancer Research, vol. 53, 1993, pp. 1484-1488.
Allen et al, Journal of Liposome Research, vol. 4(1), 1994, pp. 1-25.
Rational Basis for Chemotherapy, UCLA Symposium Molecular and Cellular Biology, published 1983, Weinstein, J.N., “Target-Direction of Liposomes: Four Strategies for Attacking Tumor Cells”, pp. 441-473.
Journal of Liposome Research, Voltage 3. No. 3, issued 1993, Jones et al, “Preparation and Characterization of Ligand-Modified Labelled Liposomes for Solid Phase Immunoassays”, pp. 793-804.
Nature, vol. 288, issued Dec. 11, 1980, Leserman et al, “Targetting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or Protein A”, pp. 602-604.
Biochemica et Biophysica Acta, vol. 1194, issued 1994, Flasher et al, Liposome Targetting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG), pp. 185-196, see pp. 193-194.
Henry et al. Improved Monoclonal antibody tumor/background ratios with exchange transfusions. Nuclear Medicine Biology. 1991, Voltage. 18, No. 5, pp. 565-567, see pp. 565.
Polster Lieder Woodruff & Lucchessi, LC
Ungar Susan
LandOfFree
Methods of treatment and diagnostic visualization,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment and diagnostic visualization,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment and diagnostic visualization,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3761880